Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has announced that Lipitor 80mg reduced the risk of heart attack and stroke by 32% in patients who have heart disease and chronic kidney disease compared with patients taking the 10mg dose of Lipitor.
Subscribe to our email newsletter
The primary endpoint of the Treating to New Targets (TNT) study was the reduction of major cardiovascular events, including death from heart disease, non-fatal heart attacks, resuscitated cardiac arrest, and fatal or non-fatal strokes. This sub-analysis studied 3,107 patients with moderate to severe chronic kidney disease, as defined using a standard measure of kidney function.
The efficacy results in this analysis were primarily driven by reductions in heart attack and stroke. Both doses of Lipitor (80mg and 10mg) were well tolerated. Lipitor 80mg is not a starting dose. The safety of Lipitor 80 mg in patients with chronic kidney disease was similar to that reported for the overall TNT population, with no unexpected safety concerns identified.
Halit Bander, senior director of Pfizer’s global cardiovascular metabolic medical team, said: “The results of this analysis complement the large body of evidence from multiple clinical trials demonstrating the cardiovascular benefits of Lipitor.”